摘要
目的 系统评价国内循环肿瘤DNA诊断乳腺癌的价值。方法 查找清华同方数据库、万方数据库、维普数据库、中国生物医学文献数据库、PubMed、EMBASE、Cochranelibrary数据库中有关国内循环肿瘤DNA诊断乳腺癌的诊断性试验,检索时限均为从建库至2017年12月21日。由2位研究者独立筛选文献、提取数据和评价纳入研究的方法学质量后,使用Meta-Disc1.4软件对纳入研究进行综合定量评价,并绘制受试者工作特征曲线(ROC曲线),对循环肿瘤DNA诊断中国人群乳腺癌的准确性进行评估,使用STATA13.0软件进行发表偏倚检验。结果 共纳入7篇文献,合并灵敏度为0.85(95%CI:0.82~0.87)、特异度为0.86(95%CI:0.84~0.89)、阳性似然比为6.477(95%CI:3.496~12.000)、阴性似然比为0.173(95%CI:0.102~0.296)、合并诊断比值比为39.94(95%CI:14.07~113.37),ROC曲线下面积为0.9285。纳入文献存在异质性,异质性来源于研究地区和目标基因。对纳入的研究作Deeks图,提示不存在明显的发表偏移。结论 循环肿瘤DNA对中国人群乳腺癌诊断价值较高,在临床实践过程中可以通过联合其他项目检测以提高对乳腺癌的诊断准确性。
Objective To systematically review the diagnostic value of circulating tumor DNA for breast cancer in China. Methods CNKI,Wanfang Data,VIP,CBM,EMBASE,Cochrane library were searched from inception to December 21,2017,to collect diagnostic studies about circulating tumor DNA for breast cancer in China.Two reviewers independently screened literature,extracted data and assessed the methodological quality of included studies.Statistic analyses were performed by software Meta-Disc1.4 vision,and summary receive operating characteristic curve (ROC curve)was performed.The publication bias test was performed using STATA 13 software. Results A total of 7 studies were finally included.The pooled sensitivity,specificity,positive likelihood ratio,negative likelihood ratio,and diagnostic odds ratio were 0.85 (95% CI :0.82-0.87),0.86 (95% CI :0.84-0.89),6.477 (95% CI :3.496-12.000),0.173 (95% CI :0.102-0.296),respectively.The pool diagnostic odds ratio was 39.94 (95% CI :14.07-113.37) and area under the ROC curve was 0.928 5 .There was heterogeneity in the included studies,and subgroup analysis suggested that heterogeneity was derived from the study area and target genes.The deeks suggested the publication bias was not significant. Conclusion Current evidence indicates that circulating tumor DNA has high diagnostic value for breast cancer in Chinese population,and the accuracy of breast cancer diagnosis can be improved by joining the other project detection in clinical practice.
作者
孙浩
张红艳
蒋紫欣
SUN Hao;ZHANG Hongyan;JIANG Zixin(Fuzhou KingMed Diagnostics Limited Company,Fuzhou,Fujian 350000,China;Department of Clinical Laboratory,Sichuan Academy of Medical Sciences/East Branch SichuanProvincial People′s Hospital,Chengdu,Sichuan 610000,China;Department ofClinical Laboratory,the Third People′s Hospital of Wuhou,Chengdu,Sichuan 610000,China)
出处
《国际检验医学杂志》
CAS
2019年第14期1741-1745,共5页
International Journal of Laboratory Medicine